From the Professor..., page-132

@reon1

There is a consistent theme of you not doing your homework. You can’t get IMU right let alone RAC. I suppose there really is only so much that I can expect from you if you openly admit that market value for an established drug class is not an important factor to consider when investing in a speculative biotechnology company.

If a drug synergises with therapies to improve efficacy and prevents known dose-limiting toxicities, then there is no competition as it harmonises with competitors for cancer indications. If a drug has to compete with known medications for cancer indications, then it is displacing the market and there is a lot of competition.

CF33 really stands out amongst the crowd so far, doesn’t it. It isn’t even close to being the best performing OV therapy, and none of those drugs are approved. How do you honestly think it will fair against approved therapies?

@jamie21s what do you think is worse, erroneous, misleading ramping or an evidence-based, thoughtful contrarian view that challenges it?

A foundation of science is critical discourse.